Skip to main content

Table 3 Demographic and clinical characteristics stratified by infection outcomes in the intent to treat study population

From: Evaluation of targeted antimicrobial prophylaxis for transrectal ultrasound guided prostate biopsy: a prospective cohort trial

 

No infection

N = 501 (98.2%)

Infection

N = 9 (1.8%)

All

N = 510

P value

Demographics

 Age, mean +/− SD, (range), years

62.5 ± 8.9 (33–88)

63.4 ± 6.5 (48–71)

62.5 ± 8.9 (33–88)

0.75

 Race, n (%)

   

1.0

  White

368 (73.5)

8 (88.9)

376 (73.7)

 

  Black

82 (16.4)

1 (11.1)

83 (16.3)

 

  Hispanic

30 (6.0)

0 (0.0)

30 (5.9)

 

  Other

21 (4.2)

0 (0.0)

21 (4.1)

 

Clinical characteristics

 Biopsy result, n (%)

   

0.611

  Negative

253 (50.5)

4 (44.4)

257 (50.4)

 

  Prostate cancer

196 (39.1)

5 (55.6)

201 (39.4)

 

  HGPIN

52 (10.4)

0 (0.0)

52 (10.2)

 

 History of urinary tract infection, n (%)

   

0.029

  Yes

52 (10.4)

3 (33.3)

55 (10.8)

 

  No

437 (87.2)

5 (55.6)

442 (86.7)

 

  Unknown/missing

12 (2.4)

1 (11.1)

13 (2.5)

 

 History of urinary retention; n (%)

   

0.499

  Yes

38 (7.6)

1 (11.1)

39 (7.6)

 

  No

410 (81.8)

8 (88.9)

418 (82.0)

 

  Unknown/missing

53 (10.6)

0 (0.0)

53 (10.4)

 

 FQ usage in prior 2 years, n (%)

   

0.678

  Yes

111 (22.2)

3 (33.3)

114 (22.3)

 

  No

263 (52.5)

4 (44.4)

267 (52.4)

 

  Unknown/missing

127 (25.3)

2 (22.2)

129 (25.3)

 

 Hospitalized in prior 1 year; n (%)

   

0.400

  Yes

46 (9.2)

2 (22.2)

48 (9.4)

 

  No

440 (87.8)

7 (77.8)

447 (87.7)

 

  Unknown/missing

15 (3.0)

0 (0.0)

15 (2.9)

 

 Healthcare worker; n (%)

   

0.713

  Yes

16 (3.2)

0 (0.0)

16 (3.1)

 

  No

418 (83.4)

9 (100)

427 (83.7)

 

  Unknown/missing

67 (13.4)

0 (0.0)

67 (13.1)

 

 Charlson comorbidity score; n (%)

   

0.139

  0

410 (81.8)

6 (66.7)

416 (81.6)

 

  1

17 (3.4)

1 (11.1)

18 (3.5)

 

  2

35 (7.0)

0 (0.0)

35 (6.9)

 

  3–16

39 (7.8)

2 (22.2)

41 (8.0)

 
  1. Abbreviations: HGPIN high-grade prostatic intraepithelial neoplasia, FQ fluoroquinolone